Our Company

1 of 1
1-2 of 2
NADAC-plus: An emerging paradigm in pharmacy pricing?14 November 2018 - By Kevin P. Pierce and Andrea Sheldon - Article

This paper introduces national average drug acquisition costs (NADAC) and describes the opportunities and limitations of using NADAC as a basis for pharmacy pricing.

Leveraging drug rebates for medical stop loss product innovation11 September 2018 - By Kevin P. Pierce and Thomas D. Murawski - Article

This paper explores potential innovations and key strategies for medical stop loss insurers.

1 of 1

  • Work at Milliman

    • “I was offered a chance to come in, shake things up, create something."
    Work at Milliman